STAC-9

STAC-9 is an experimental drug that was developed by GlaxoSmithKline as a small-molecule activator of the sirtuin subtype SIRT1, with potential applications in the treatment of diabetes.
Wikipedia contributors, "STAC-9", Wikipedia, revision 1370537352, retrieved 20 November 2026, source, CC BY-SA 4.0.